USBC, Inc. Q3 FY2024 Earnings Call
· Earnings call transcript and AI-powered summary
- Date: Not specified (Q3 Fiscal 2024)
- Company: Know Labs
- Presenters: Ron Erickson (Chairman & CEO), Pete Conley (CFO & SVP of Intellectual Property)
Key Operational Highlights
- KnowU CGM Device: Successfully miniaturized and launched KnowU, an 85% smaller, wearable continuous glucose monitor only eight months after the Gen1 prototype launch. Companion mobile app introduced.
- Clinical Trials: Multiple studies presented at leading conferences. Most notable MARD (Mean Absolute Relative Difference) values:
- 11.8% – American Diabetes Association (84th Sessions)
- 11.1% – American Association of Clinical Endocrinology 2024
- 10.8% – American Physiological Society Summit
- 11.1% – ATTD Conference, Florence, Italy
- New Study Published: Peer-reviewed article in Diabetes Technology and Therapeutics, showing 93.37% accuracy in glycemic classification using RF technology.
- Device Testing: Expanded testing in diverse populations and glycemic ranges. Continuous data collection enabled through the wearable device format.
Continue Reading
Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.
Upgrade to ProfessionalContinue Reading
Unlock the full earnings call transcript with speaker labels and formatted dialogue.
Upgrade to Professional